Premium
IC‐P‐020: Comparison of nia‐aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers
Author(s) -
Gordon Brian Andrew,
Vos Stephanie,
Morris John C.,
Holtzman David M.,
Fagan Anne M.,
Benzinger Tammie L.S.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.06.040
Subject(s) - neuroimaging , alzheimer's disease neuroimaging initiative , dementia , clinical dementia rating , oncology , pittsburgh compound b , biomarker , psychology , medicine , cerebrospinal fluid , pathology , neuropsychology , disease , cognition , neuroscience , biology , biochemistry
diagnostic categories (UCLA/Leuven-NC DSUVR1⁄40.06, p1⁄40.01; MCI DSUVR1⁄40.13, p<0.0001; dementia DSUVR1⁄40.04, p1⁄40.0007). An effect was also seen for parietal SUVR in MCI (DSUVR1⁄40.1, p1⁄40.0004) and UCLA/Leuven-NC (DSUVR1⁄40.05, p1⁄40.04) as well as in frontal (DSUVR1⁄40.09, p1⁄40.0006) temporal (DSUVR1⁄40.08, p1⁄40.005), occipital (DSUVR1⁄40.1, p1⁄40.0004) and basal ganglia (DSUVR1⁄40.08, p1⁄40.0016) SUVR in MCI only. Conclusions:Higher SUVR is associated with worse cognitive performance in both the cognitively normal and impaired stages. Most significant SUVR increases per unit MMSE were seen in MCI, followed by NC and finally demented subjects in agreement with the sigmoid curve of increasing amyloid deposition.